Testing for liver scarring at the diabetes annual review

Not Applicable

• Conditions: iver fibrosis; Digestive System; Fibrosis and cirrhosis of liver

• Registration Number: ISRCTN14585543
• Lead Sponsor: Queen Mary University of London

Brief Summary

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37208139/ (added 22/05/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-04-27
• Last Update Posted: 5 June 2023
• Study Completion: 2023-11-02

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 5300

Inclusion Criteria

1. General practice with >4000 registered patients
2. Practice lead, or representative, confirms agreement to participate in the study after reading the practice information sheet
3. Practice lead, or representative, confirms practice support introduction of Fib-4 testing for all patients with type 2 diabetes attending for annual review
4. Track record of >85% of patients with type 2 diabetes attending for diabetes review
5. Practice uses EMIS computer system
6. Referral route for fibroscan based on primary care non-invasive score agreed

Patient inclusion criteria:
1. Type 2 diabetes
2. Serum biochemistry sample taken alongside diabetes annual review

Exclusion Criteria

1. Inclusion criteria not met
2. Practice participating in other screening or case-finding study related to liver fibrosis

Study & Design

• Study Type: Interventional
• Study Design: Not specified